Showing results (751-760 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|April 6, 2007
CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell typeStefania Scala, Caterina Ieranò, Alessandro Ottaiano, et al.Cancer Immunology, Immunotherapy : CII|April 20, 2006
Identification of different tumor escape mechanisms in several metastases from a melanoma patient undergoing immunotherapyRosa Méndez, Francisco Ruiz-Cabello, Teresa Rodríguez, et al.Cancer Immunology, Immunotherapy : CII|June 20, 2006
Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccineMatthew T Hueman, Alexander Stojadinovic, Catherine E Storrer, et al.Cancer Immunology, Immunotherapy : CII|May 9, 2006
Epigenetic regulation of immune escape genes in cancerThomas B Tomasi, William J Magner, A Nazmul H KhanCancer Immunology, Immunotherapy : CII|May 13, 2006
Virology- and immunology-based gene therapy for cancerMasatoshi Tagawa, Kiyoko Kawamura, Osamu Shimozato, et al.Cancer Immunology, Immunotherapy : CII|January 11, 1991
Cytotoxic activity toward mouse melanoma following immunization of mice with transfected cells expressing a human melanoma-associated antigenJ Nowak, E P Cohen, L H GrafCancer Immunology, Immunotherapy : CII|July 14, 2007
MAGE-A3(161-175) contains an HLA-DRbeta4 restricted natural epitope poorly formed through indirect presentation by dendritic cellsJill Marturano, Renato Longhi, Giulia Casorati, et al.Cancer Immunology, Immunotherapy : CII|July 14, 2007
Expression of a dendritic cell maturation marker CD83 on tumor cells from lung cancer patients and several human tumor cell lines: is there a biological meaning behind it?R B Baleeiro, P C Bergami-Santos, M Y Tomiyoshi, et al.Cancer Immunology, Immunotherapy : CII|August 29, 2007
A simple but effective cancer vaccine consisting of an antigen and a cationic lipidWeihsu Chen, Weili Yan, Leaf HuangCancer Immunology, Immunotherapy : CII|August 29, 2007
The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytesJames A Thompson, Minu K Srivastava, Jacobus J Bosch, et al.Pageof 650